

FILE COPY

July 24, 2002

Joseph K. Belanoff, M.D.
Chief Executive Officer
Corcept Therapeutics Incorporated
275 Middlefield Road, Suite A
Menlo Park, CA 94025

Dear Dr. Belanoff:

Your petition requesting the Food and Drug Administration to initiate an investigation, to determine that The Population Council did not act with due diligence during the regulatory review period for MIFEPREX (mifepristone), and revise accordingly the period eligible for patent extension was received by this office on 07/24/02. It was assigned docket number 01E-0363/CP 1 and it was filed on 07/24/02. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,



Lyle D. Jaffe
Dockets Management Branch

01E-0363

ACK 1